Patient info Open main menu

Tegretol 400 mg prolonged-release tablets – Summary of Product Characteristics (SmPC) for healthcare professionals

Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet: how to take, side effects, pregnancy and breast-feeding.

Medicine strength:
400 mg
Contains active substance:
Similar medicines:

Summary of Product Characteristics (SmPC) - Tegretol 400 mg prolonged-release tablets

1. NAME OF THE MEDICINAL PRODUCT

Not Applicable

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Not Applicable

3. PHARMACEUTICAL FORM

Not Applicable

4. CLINICAL PARTICULARS

4.1. Therapeutic indications

Not Applicable

4.2. Posology and method of administration

Not Applicable

4.3. Contraindications

Not Applicable

4.4. Special warnings and precautions for use

Not Applicable

4.5. Interactions with other medicinal products and other forms of interaction

Not Applicable

4.6. Pregnancy and lactation

Not Applicable

4.7. Effects on ability to drive and use machines

Not Applicable

4.8. Undesirable effects

Not Applicable

4.9. Overdose

Not Applicable

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic properties

Not Applicable

5.2. Pharmacokinetic properties

Not Applicable

5.3. Preclinical safety data

Not Applicable

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Not Applicable

6.2. Incompatibilities

Not Applicable

6.3. Shelf life

Not Applicable

6.4. Special precautions for storage

Not Applicable

6.5. Nature and contents of container

Not Applicable

6.6. Instruction for use and handling (, and disposal)

Not Applicable

No Data Held

Administrative Data

7. MARKETING AUTHORISATION HOLDER

Not Applicable

8. MARKETING AUTHORISATION NUMBER

Not Applicable

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Not Applicable

10. DATE OF REVISION OF THE TEXT

Not Applicable

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLPI 20774/0617

MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Tegretol 400 mg prolonged-release tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Carbamazepine
Strength 400 mg
Pharmaceutical form Modified-release tablet
How is it taken Oral
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Drug group (ATC)
  1. N Nervous system drugs
    1. N03 Antiepileptics
      1. N03A Antiepileptics
        1. N03AF Carboxamide derivatives, antiepileptics
          1. N03AF01 carbamazepine
Marketing authorisation PLPI 16378/0774, PLPI 20774/0617
Codes BNF 04080100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.